BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:131I-apamistamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of 131I-apamistamab\, from ClinicalTrials.go
 v estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04512716-3053@assetmemo.bio
DTSTAMP:20261121T005931Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:131I-apamistamab: Phase 1 readout est. (NCT04512716)
DESCRIPTION:131I-apamistamab\, phase 1.\nStudy: Iomab-ACT: A Pilot Study of
  131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patien
 ts With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diff
 use Large B-Cell Lymphoma\nEstimated primary completion: January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/131i-apamistamab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04512716
URL:https://assetmemo.bio/drug/131i-apamistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07157514-3053@assetmemo.bio
DTSTAMP:20261121T005931Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:131I-apamistamab: Phase 2/3 readout est. (NCT07157514)
DESCRIPTION:131I-apamistamab\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: 
 Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Tran
 splant in Relapse/Refractory AML\nEstimated primary completion: February 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/131i-apamistamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 57514
URL:https://assetmemo.bio/drug/131i-apamistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06768905-3053@assetmemo.bio
DTSTAMP:20261121T005931Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:131I-apamistamab: Phase 1/2 readout est. (NCT06768905)
DESCRIPTION:131I-apamistamab\, phase 1/2.\nStudy: IOMAB-CAR-T Followed by C
 AR-T Cell Therapy in R/R DLBCL\nEstimated primary completion: May 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/131i-apamistamab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06768905
URL:https://assetmemo.bio/drug/131i-apamistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07015684-3053@assetmemo.bio
DTSTAMP:20261121T005931Z
DTSTART;VALUE=DATE:20300312
DTEND;VALUE=DATE:20300313
SUMMARY:131I-apamistamab: Phase 1 readout est. (NCT07015684)
DESCRIPTION:131I-apamistamab\, phase 1.\nStudy: 131I-apamistamab-based Cond
 itioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle 
 Cell Disease (SCD)\nEstimated primary completion: 12 March 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/131i-apamistamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07015684
URL:https://assetmemo.bio/drug/131i-apamistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
